ATAGI statement on Nirsevimab 2024

ATAGI statement on Nirsevimab for the prevention of severe disease due to respiratory syncytial virus (RSV) in infants.

Downloads

Publication ATAGI statement on Nirsevimab 2024

ATAGI has provided clinical advice on the use of Nirsevimab (Beyfortus, Sanofi-Aventis) for the prevention of severe disease due to respiratory syncytial virus (RSV) infection in infants. 

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Publication type:
Fact sheet
Audience:
Health sector
Language:
English

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.